Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...

A trade group representing large compounding pharmacies sued the FDA over its removal of a widely prescribed Lilly diabetes ...

NanoViricides, Inc. (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman ...

A persistent infection could explain why some people experience long COVID symptoms, according to a new study led by researchers at Brigham and Women’s Hospital. The team found evidence of persistent ...

Most investors unaware of the huge breakthroughs happening in biotech right now. But new technologies such as cancer-killing ...

Researchers at Brigham and Women's Hospital discovered that individuals exhibiting a wide range of long COVID symptoms were ...

Dealmaking is up this year and doesn’t look like it will slow down in 2025. Merck is an example of a company that could ...

Brigham researchers found people with wide-ranging long COVID symptoms were twice as likely to have SARS-CoV-2 proteins in their blood, compared to ...

A new trial reveals that weekly injections of the weight-loss drug Wegovy (semaglutide) lowered the risk of death from COVID-19 by about a third and reduced overall mortality by 19%.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Today, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead of future pandemics, released its ...